Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IL1B | P01584 | 14/20 | 0.78 |
| ▸ | NLRP3 | Q96P20 | 10/20 | 0.78 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.66 |
| ▸ | TNF | P01375 | 3/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24575379 | 0.91 | IL1B (0.78) | IL1BNLRP3KCNH2TNF | |
| SCHEMBL31057433 | 0.90 | IL1B (0.77) | IL1BNLRP3KCNH2TNF | |
| SCHEMBL31021458 | 0.90 | IL1B (0.63) | IL1BNLRP3KCNH2TNF | |
| SCHEMBL31057269 | 0.89 | IL1B (0.73) | IL1BNLRP3KCNH2TNF | |
| SCHEMBL31057421 | 0.89 | IL1B (0.73) | IL1BNLRP3KCNH2TNF | |
| SCHEMBL29307326 | 0.89 | IL1B (0.73) | IL1BNLRP3KCNH2TNF | |
| Hydrochloric Acid SCHEMBL31057343 | 0.89 | IL1B (0.76) | IL1BNLRP3KCNH2TNF | |
| SCHEMBL31057209 | 0.89 | IL1B (0.76) | IL1BNLRP3KCNH2TNF | |
| SCHEMBL31057252 | 0.89 | IL1B (0.75) | IL1BNLRP3KCNH2TNF | |
| SCHEMBL31057304 | 0.89 | IL1B (0.75) | IL1BNLRP3KCNH2TNF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4347571-B1 | TRIAZINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF CANCER. | HOFFMANN LA ROCHE (CH) | 2026-04-22 | — | — | EP | disclosed |
| US-12421209-B2 | Compounds | HOFFMANN-LA ROCHE INC. (US) | 2025-09-23 | — | — | US | disclosed |
| US-20250276958-A1 | COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2025-09-04 | — | — | US | disclosed |
| EP-4609865-A2 | NLRP3 INHIBITORS | F. Hoffmann-La Roche AG (CH) | 2025-09-03 | — | — | EP | disclosed |
| US-20250197370-A1 | NOVEL COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2025-06-19 | — | — | US | disclosed |
| EP-4337652-B1 | NLRP3 INHIBITORS | HOFFMANN LA ROCHE (CH) | 2025-04-09 | — | — | EP | disclosed |
| EP-4433459-A1 | PYRIDAZINE DERIVATIVES AS INHIBITORS OF NLRP3 | F. Hoffmann-La Roche AG (CH) | 2024-09-25 | — | — | EP | disclosed |
| US-20240308977-A1 | PYRIDAZINE DERIVATIVES AS INHIBITORS OF NLRP3 | HOFFMANN-LA ROCHE INC. (US) | 2024-09-19 | — | — | US | disclosed |
| CN-118265701-A | Pyridazine derivatives as inhibitors of NLRP3 | 豪夫迈·罗氏有限公司 | 2024-06-28 | — | — | CN | disclosed |
| US-20240208928-A1 | NOVEL COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2024-06-27 | — | — | US | disclosed |
| US-20240208928-A1 | NOVEL COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2024-06-27 | — | — | US | disclosed |
| US-20240132471-A1 | NOVEL COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2024-04-25 | — | — | US | disclosed |
| EP-4347571-A1 | TRIAZINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF CANCER | F. Hoffmann-La Roche AG (CH) | 2024-04-10 | — | — | EP | disclosed |
| EP-4337652-A1 | NLRP3 INHIBITORS | F. Hoffmann-La Roche AG (CH) | 2024-03-20 | — | — | EP | disclosed |
| WO-2023088987-A1 | PYRIDAZINE DERIVATIVES AS INHIBITORS OF NLRP3 | F. HOFFMANN-LA ROCHE AG (CH) | 2023-05-25 | — | — | WO | disclosed |
| WO-2022253936-A1 | TRIAZINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF CANCER. | F. HOFFMANN-LA ROCHE AG (CH) | 2022-12-08 | — | — | WO | disclosed |
| WO-2022253936-A1 | TRIAZINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF CANCER. | F. HOFFMANN-LA ROCHE AG (CH) | 2022-12-08 | — | — | WO | disclosed |
| WO-2022238347-A1 | NLRP3 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2022-11-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12421209-B2 | Compounds | C5, RB1, RPS4X | IL1B 4014/4885NLRP3 3643/4885KCNH2 787/4885 |
| US-20240308977-A1 | PYRIDAZINE DERIVATIVES AS INHIBITORS OF NLRP3 | NLRP3, NLRP1, PYCARD | IL1B 8/4885NLRP3 1/4885KCNH2 867/4885 |
| US-20240208928-A1 | NOVEL COMPOUNDS | RB1, RPS4X, RPS4Y1 | IL1B 3466/4885NLRP3 3164/4885KCNH2 1568/4885 |
| US-20250276958-A1 | COMPOUNDS | C5, RB1, RPS4X | IL1B 4014/4885NLRP3 3643/4885KCNH2 787/4885 |
| US-20250197370-A1 | NOVEL COMPOUNDS | RB1, CDK11B, RPS4X | IL1B 3429/4885NLRP3 3053/4885KCNH2 1661/4885 |
| US-20240132471-A1 | NOVEL COMPOUNDS | RB1, RPS4Y1, CDK11B | IL1B 3239/4885NLRP3 3180/4885KCNH2 1742/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.